Anixa Biosciences Says COVID-19 Compounds Potentially Effective Against Omicron Variant


Anixa Biosciences Inc ANIX announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH, on potential compounds to treat COVID-19. 

  • The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant of the virus. 
  • Related Link: Anixa Biosciences' COVID-19 Compounds Show Potential Efficacy Against Delta Variant.
  • Anixa and MolGenie are developing compounds for the potential treatment of COVID-19 with the long-term goal of creating an inexpensive, orally-administered room temperature-stable pill for the outpatient setting. 
  • The program focuses on identifying novel, small molecule inhibitors of Mpro, the main protease of the SARS-CoV-2 virus, necessary for replication. 
  • The current compounds that Anixa and MolGenie have synthesized and tested have demonstrated the ability to inhibit the function of this protein with favorable potency comparable to authorized therapies.
  • Price Action: ANIX shares are up 1.60% at $3.18 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusPreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!